A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Clinical trial NCT07196644 · RECRUITING

Trial details

NCT number: NCT07196644
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Solid Tumors Harboring MET Amplification

Start date: 2025-12-01
Primary completion: 2030-12-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.